BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Disc Medicine (NASDAQ: IRON) and increased the price target from $100 to $120. This adjustment reflects a positive outlook for the company's performance in the market.